Pharsight

Adempas patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6743798 BAYER HLTHCARE Substituted pyrazole derivatives condensed with six-membered heterocyclic rings
Jul, 2019

(4 years ago)

US7173037 BAYER HLTHCARE Carbamate-substituted pyrazolopyridines
Dec, 2026

(2 years from now)

US11203593 BAYER HLTHCARE Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
Feb, 2034

(9 years from now)

US10662188 BAYER HLTHCARE Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate
Feb, 2034

(9 years from now)

Adempas is owned by Bayer Hlthcare.

Adempas contains Riociguat.

Adempas has a total of 4 drug patents out of which 1 drug patent has expired.

Expired drug patents of Adempas are:

  • US6743798

Adempas was authorised for market use on 08 October, 2013.

Adempas is available in tablet;oral dosage forms.

Adempas can be used as treatment of adults with pulmonary hypertension (pah), (who group 1), to improve exercise capacity, who functional class and to delay clinical worsening, treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (cteph), (who group 4) after surgical treatment, or inoperable cteph, to improve exercise capacity and who functional class.

Drug patent challenges can be filed against Adempas from 08 October, 2017.

The generics of Adempas are possible to be released after 18 February, 2034.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Oct 08, 2020
New Chemical Entity Exclusivity(NCE) Oct 08, 2018
Orphan Drug Exclusivity(ODE-53) Oct 08, 2020

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using RIOCIGUAT ingredient

NCE-1 date: 08 October, 2017

Market Authorisation Date: 08 October, 2013

Treatment: Treatment of adults with pulmonary hypertension (pah), (who group 1), to improve exercise capacity, who functional class and to delay clinical worsening; Treatment of adults with persistent/recurrent ...

Dosage: TABLET;ORAL

How can I launch a generic of ADEMPAS before it's drug patent expiration?
More Information on Dosage

ADEMPAS family patents

Family Patents